Core Insights - Polaryx Therapeutics, Inc. has appointed three new members to its Board of Directors, enhancing its expertise in scientific research, clinical development, finance, and corporate strategy as it progresses as a public company [1][2][3] Board Appointments - Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. have been appointed to the Board, effective January 29, 2026, while Andrew O has ceased to serve [1][2] - The new board members bring extensive experience: Dr. Berger is a prominent figure in neuro-oncology, Mr. Braun has a strong background in finance and advisory roles, and Dr. Ryan has significant experience in biotechnology and regulatory affairs [3][4][5][6] Company Milestones - Polaryx is advancing its lead candidate, PLX-200, into an IND-approved SOTERIA Phase 2 basket trial, marking a significant near-term milestone for the company [2][3] - The company focuses on developing therapies for rare, pediatric lysosomal storage disorders (LSDs), aiming to address significant unmet medical needs [7]
Polaryx Therapeutics Welcomes New Members of the Board of Directors